文献速递免疫规划

新型猪源悬浮细胞系PBG.PK2.1高密度培养高效生产甲型流感病毒

Efficient influenza A virus production in high cell density using the novel porcine suspension cell line PBG.PK2.1.
PubMed 文献 · Vaccine · 2019-04-17

本文介绍ProBioGen AG开发的新型哺乳动物细胞系PBG.PK2.1(源于永生化猪肾细胞,已适应无化学定义培养基悬浮生长)用于流感疫苗生产。通过病毒适应和感染条件优化,在补料分批生物反应器(700 mL工作体积)中血凝素滴度达3.24 log10(HA units/100 µL);在中空纤维ATF2高密度培养中细胞浓度达50 × 10^6 cells/mL、活率超95%、最高HA滴度3.93 log10(HA units/100 µL)。病毒HA糖基化与MDCK或Vero细胞生产的HA存在明显差异,平均细胞特异性产率为5000 virions/cell。

要点

  • PBG.PK2.1悬浮细胞在补料分批反应器中HA滴度达3.24 log10(HA units/100 µL)。
  • ATF2高密度培养细胞浓度达50 × 10^6 cells/mL,活率超95%,HA滴度3.93 log10(HA units/100 µL)。
  • 病毒HA糖基化与MDCK或Vero细胞生产的HA存在明显差异。

核心结论

  • PBG.PK2.1细胞平均细胞特异性产率达5000 virions/cell,被认为是下一代流感疫苗生产的非常有前景的候选细胞系。

研究设计与样本

  • 研究评估ProBioGen AG开发的新型永生化猪肾来源哺乳动物细胞系PBG.PK2.1,该细胞已适应无化学定义培养基悬浮生长。
  • 在补料分批生物反应器(700 mL工作体积)和中空纤维ATF2高密度培养系统中评估流感病毒生产,并优化感染复数与胰蛋白酶浓度。

主要发现

  • 补料分批生物反应器中血凝素滴度最高达3.24 log10(HA units/100 µL)。
  • ATF2高密度培养中细胞浓度达50 × 10^6 cells/mL,活率超过95%,最高HA滴度3.93 log10(HA units/100 µL)。
  • 病毒HA糖基化与MDCK或Vero细胞系生产的HA相比存在明显差异。

临床怎么用

  • PBG.PK2.1悬浮细胞可用于流感疫苗生产的细胞培养病毒扩增,支持高密度培养工艺开发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Seasonal and pandemic influenza respiratory infections are still a major public health issue. Vaccination is the most efficient way to prevent influenza infection. One option to produce influenza vaccines is cell-culture based virus propagation. Different host cell lines, such as MDCK, Vero, AGE1.CR or PER.C6 cells have been shown to be a good substrate for influenza virus production. With respect to the ease of scale-up, suspension cells should be preferred over adherent cells. Ideally, they should replicate different influenza virus strains with high cell-specific yields. Evaluation of new cell lines and further development of processes is of considerable interest, as this increases the number of options regarding the design of manufacturing processes, flexibility of vaccine production and efficiency. Here, PBG.PK2.1, a new mammalian cell line that was developed by ProBioGen AG (Germany) for virus production is presented. The cells derived from immortal porcine kidney cells were previously adapted to growth in suspension in a chemically-defined medium. Influenza virus production was improved after virus adaptation to PBG.PK2.1 cells and optimization of infection conditions, namely multiplicity of infection and trypsin concentration. Hemagglutinin titers up to 3.24 log10(HA units/100 µL) were obtained in fed-batch mode in bioreactors (700 mL working volume). Evaluation of virus propagation in high cell density culture using a hollow-fiber based system (ATF2) demonstrated promising performance: Cell concentrations of up to 50 × 106 cells/mL with viabilities exceeding 95%, and a maximum HA titer of 3.93 log10(HA units/100 µL). Analysis of glycosylation of the viral HA antigen expressed showed clear differences compared to HA produced in MDCK or Vero cell lines. With an average cell-specific productivity of 5000 virions/cell, we believe that PBG.PK2.1 cells are a very promising candidate to be considered for next-generation influenza virus vaccine production.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gränicher G, Coronel J, Pralow A, et al. Efficient influenza A virus production in high cell density using the novel porcine suspension cell line PBG.PK2.1. Vaccine. 2019. PMID: 31005427. doi:10.1016/j.vaccine.2019.04.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。